株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ラテンアメリカの核酸検査 (NAT) 市場:売上高の予測、サプライヤーの市場シェア・戦略 - 感染症・遺伝子疾患・がん検査、法医学的検査、父子鑑定

2017 Latin America Nucleic Acid Testing (NAT) Market: Sales Forecasts, Supplier Strategies-Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing

発行 Venture Planning Group 商品コード 445416
出版日 ページ情報 英文 1150 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.31円で換算しております。

Local License: 同一事業所内

ラテンアメリカの核酸検査 (NAT) 市場:売上高の予測、サプライヤーの市場シェア・戦略 - 感染症・遺伝子疾患・がん検査、法医学的検査、父子鑑定 2017 Latin America Nucleic Acid Testing (NAT) Market: Sales Forecasts, Supplier Strategies-Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing
出版日: ページ情報: 英文 1150 Pages
概要

当レポートでは、ラテンアメリカ諸国における核酸検査 (NAT) の市場について分析し、検査手法 (分子診断薬ほか) の概要や現在の技術水準、主な診断薬・検査薬、国別・疾患別・検査手法別の動向見通し (今後5年間分)、主要サプライヤーのプロファイル・製品ポートフォリオ・事業戦略、今後の市場機会などを調査・推計しております。

目次・図表一覧

国別の市場動向

  • アルゼンチン
  • ブラジル
  • チリ
  • コロンビア
  • メキシコ
  • ペルー
  • ベネズエラ

各種疾患向け分子診断薬の開発・上市状況

  • AIDS
  • アデノウイルス
  • バルトネラ菌
  • カンピロバクター
  • カンジダ
  • クラミジア
  • クロストリジウム
  • コロナウイルス
  • クリプトストリジウム
  • サイトメガロウイルス (CMV)
  • エコーウイルス
  • エンテロウイルス
  • エプスタイン・バーウイルス (EBV)
  • ジアルジア
  • 淋病
  • ハンタウイルス
  • ヘリコバクター
  • 肝炎
  • ヘルペス
  • インフルエンザ
  • レジオネラ菌
  • ライム病
  • 麻疹
  • 髄膜炎
  • 単核症
  • おたふく風邪
  • マイコプラズマ
  • 肺炎
  • 呼吸器合胞体ウイルス (RSV)
  • ロタウイルス
  • 風疹
  • サルモネラ菌
  • 敗血症
  • 細菌性赤痢
  • 連鎖球菌
  • 梅毒
  • トキソプラズマ
  • トリコモナス
  • 結核
  • がん
  • 遺伝子疾患
目次
Product Code: VPNAT23287

This new 7-country report from VPGMarketResearch.com is available by country, market segment, section, or individual test.

The report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during the next five years.

Highlights

- Five-year test volume and sales forecasts

- Strategic profiles of market players and start-up firms developing innovative technologies and products

- Emerging technologies

- Review of molecular diagnostic analyzers

- Specific product and business opportunities for instrument and consumable suppliers

Rationale

The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods.

In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.

Country Analyses

Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela

Market Segmentation Analysis

Five-year test volume and sales forecasts for major applications, including:

- Infectious Diseases        - Forensic Testing
- Cancer                                 - Paternity Testing/HLA Typing
- Genetic Diseases             - Others

- Five-year test volume and sales projections for over 30 NAT assays.

- A comprehensive analysis of the sequencing market, by country and laboratory segment,
  including:

- Industrial        - Academic
- Government  - Commercial

- Market segmentation analysis, including review of the market dynamics, trends, structure, size, growth and suppliers in major countries.

Product/Technology Review

- Comparison of leading molecular diagnostic analyzers marketed by Abbott, Beckman Coulter, BD, Bio-Rad, Gen-Probe, Roche, Tecan and other suppliers.

- Extensive review of molecular diagnostic technologies, test formats, detection methodologies, trends in testing automation and over 30 target/signal amplification methods, including:

- PCR     - bDNA SDA     - NASBA TMA    - SSSR, and others LCR

- Universities and research centers developing new molecular diagnostic technologies and products.

Competitive Assessments

- Extensive strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new technologies/products in R&D.

- Companies developing and marketing molecular diagnostics products, by test and application.

Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

- Business planning issues and concerns.

Contains 1,150 pages and 73 tables

Table of Contents

List of Tables

  • Argentina
  • Molecular Diagnostics Test Volume and Sales Forecasts by Application
  • Argentina
  • Molecular Diagnostics Test Volume Forecasts by Application
  • Argentina
  • Major Infectious Disease Test Volume Forecasts by Assay
  • Argentina
  • Molecular Diagnostics Market Forecasts by Application
  • Argentina
  • Major Infectious Disease Diagnostics Market Forecasts by Assay
  • Brazil
  • Molecular Diagnostics Test Volume and Sales Forecasts by Application
  • Brazil
  • Molecular Diagnostics Test Volume Forecasts by Application
  • Brazil
  • Major Infectious Disease Test Volume Forecasts by Assay
  • Brazil
  • Molecular Diagnostics Market Forecasts by Application
  • Brazil
  • Major Infectious Disease Diagnostics Market Forecasts by Assay
  • Chile
  • Molecular Diagnostics Test Volume and Sales Forecasts by Application
  • Chile
  • Molecular Diagnostics Test Volume Forecasts by Application
  • Chile
  • Major Infectious Disease Test Volume Forecasts by Assay
  • Chile
  • Molecular Diagnostics Market Forecasts by Application
  • Chile
  • Major Infectious Disease Diagnostics Market Forecasts by Assay
  • Colombia
  • Molecular Diagnostics Test Volume and Sales Forecasts by Application
  • Colombia
  • Molecular Diagnostics Test Volume Forecasts by Application
  • Colombia
  • Major Infectious Disease Test Volume Forecasts by Assay
  • Colombia
  • Molecular Diagnostics Market Forecasts by Application
  • Colombia
  • Major Infectious Disease Diagnostics Market Forecasts by Assay
  • Mexico
  • Molecular Diagnostics Test Volume and Sales Forecasts by Application
  • Mexico
  • Molecular Diagnostics Test Volume Forecasts by Application
  • Mexico
  • Major Infectious Disease Test Volume Forecasts by Assay
  • Mexico
  • Molecular Diagnostics Market Forecasts by Application
  • Mexico
  • Major Infectious Disease Diagnostics Market Forecasts by Assay
  • Peru
  • Molecular Diagnostics Test Volume and Sales Forecasts by Application
  • Peru
  • Molecular Diagnostics Test Volume Forecasts by Application
  • Peru
  • Major Infectious Disease Test Volume Forecasts by Assay
  • Peru
  • Molecular Diagnostics Market Forecasts by Application
  • Peru
  • Major Infectious Disease Diagnostics Market Forecasts by Assay
  • Venezuela
  • Molecular Diagnostics Test Volume and Sales Forecasts by Application
  • Venezuela
  • Molecular Diagnostics Test Volume Forecasts by Application
  • Venezuela
  • Major Infectious Disease Test Volume Forecasts by Assay
  • Venezuela
  • Molecular Diagnostics Market Forecasts by Application
  • Venezuela
  • Major Infectious Disease Diagnostics Market Forecasts by Assay
  • Major Companies Developing or Marketing AIDS Molecular
  • Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Adenovirus
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Bartonella
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Campylobacter
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Candida
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Chlamydia
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Clostridium
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Coronavirus
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Cryptosporidium
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing CMV Molecular
  • Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Echovirus Molecular
  • Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Enterovirus Molecular
  • Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing EBV Molecular
  • Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Giardia
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Gonorrhea
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Hantavirus
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Helicobacter
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Hepatitis
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Herpes
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Influenza
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Legionella
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Lyme
  • Disease Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Measles
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Meningitis
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Mononucleosis
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Mumps
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Mycoplasma
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Pneumonia
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing RSV
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Rotavirus
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Rubella
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Salmonella
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Septicemia
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Shigella
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Streptococci
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Syphilis
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Toxoplasmosis
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Trichomonas
  • Molecular Diagnostic and Other Direct Identification Tests
  • Major Companies Developing or Marketing Tuberculosis
  • Molecular Diagnostic and Other Direct Identification Tests
  • Oncogenes Potential Application in Cancer Diagnosis
  • Major Companies Developing or Marketing Cancer
  • Molecular Diagnostic Tests
  • Major Companies Developing or Marketing Molecular
  • Diagnostic Tests for Genetic Diseases